Zomedica Corp (ZOM)

Overview News Price History Discussions Forecast

Zomedica Corp stock is currently priced at $0.1301, with a 24-hour trading volume of 3.83M. It has seen a +5.17% increased in the last 24 hours and a -5.72% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $0.1253 pivot point. If it approaches the $0.133 resistance level, significant changes may occur.

Zomedica Corp Stock (ZOM) Financials Data

Zomedica Corp (ZOM) Revenue 2024

ZOM reported a revenue (TTM) of $25.19 million for the quarter ending December 31, 2023, a +33.05% rise year-over-year.

Zomedica Corp (ZOM) Net Income 2024

ZOM net income (TTM) was -$34.53 million for the quarter ending December 31, 2023, a -102.96% decrease year-over-year.

Zomedica Corp (ZOM) Cash Flow 2024

ZOM recorded a free cash flow (TTM) of -$20.62 million for the quarter ending December 31, 2023, a -62.42% decrease year-over-year.

Zomedica Corp (ZOM) Earnings per Share 2024

ZOM earnings per share (TTM) was -$0.036 for the quarter ending December 31, 2023, a -111.76% decline year-over-year.

Zomedica Pharmaceuticals Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. The company's lead drug product candidate is ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs. It is also developing ZM-007, an oral suspension formulation of metronidazole for the treatment of acute diarrhea in small dog breeds and puppies; ZM-006, a transdermal gel formulation of methimazole targeting hyperthyroidism in cats; and ZM-011, a transdermal gel formulation of fluoxetine for the treatment of feline behavioral disorders, such as inappropriate urination. The company has a collaboration agreement with Celsee Diagnostics, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and with Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. Zomedica Pharmaceuticals Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.